Search Results - "Kim, Haesook T"

Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis by KIM, Haesook T

“…Competing risks occur commonly in medical research. For example, both treatment-related mortality and disease recurrence are important outcomes of interest and…”
Get full text

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation by Armand, Philippe, Kim, Haesook T., Logan, Brent R., Wang, Zhiwei, Alyea, Edwin P., Kalaycio, Matt E., Maziarz, Richard T., Antin, Joseph H., Soiffer, Robert J., Weisdorf, Daniel J., Rizzo, J. Douglas, Horowitz, Mary M., Saber, Wael

“…Because the outcome of allogeneic hematopoietic cell transplantation (HCT) is predominantly influenced by disease type and status, it is essential to be able…”
Get full text

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity by Lampson, Benjamin L., Kasar, Siddha N., Matos, Tiago R., Morgan, Elizabeth A., Rassenti, Laura, Davids, Matthew S., Fisher, David C., Freedman, Arnold S., Jacobson, Caron A., Armand, Philippe, Abramson, Jeremy S., Arnason, Jon E., Kipps, Thomas J., Fein, Joshua, Fernandes, Stacey, Hanna, John, Ritz, Jerome, Kim, Haesook T., Brown, Jennifer R.

“…Idelalisib is a small-molecule inhibitor of PI3Kδ with demonstrated efficacy for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). To…”
Get full text

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma by Merryman, Reid W., Kim, Haesook T., Zinzani, Pier Luigi, Carlo-Stella, Carmelo, Ansell, Stephen M., Perales, Miguel-Angel, Avigdor, Abraham, Halwani, Ahmad S., Houot, Roch, Marchand, Tony, Dhedin, Nathalie, Lescaut, Willy, Thiebaut-Bertrand, Anne, François, Sylvie, Stamatoullas-Bastard, Aspasia, Rohrlich, Pierre-Simon, Labussière Wallet, Hélène, Castagna, Luca, Santoro, Armando, Bachanova, Veronika, Bresler, Scott C., Srivastava, Amitabh, Kim, Harim, Pesek, Emily, Chammas, Marie, Reynolds, Carol, Ho, Vincent T., Antin, Joseph H., Ritz, Jerome, Soiffer, Robert J., Armand, Philippe

“…Anti–programmed cell death protein 1 (PD-1) monoclonal antibodies are being increasingly tested in patients with advanced lymphoma. Following treatment, many…”
Get full text

Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation by Gibson, Christopher J, Kim, Haesook T, Zhao, Lin, Murdock, H Moses, Hambley, Bryan, Ogata, Alana, Madero-Marroquin, Rafael, Wang, Shiyu, Green, Lisa, Fleharty, Mark, Dougan, Tyler, Cheng, Chi-An, Blumenstiel, Brendan, Cibulskis, Carrie, Tsuji, Junko, Duran, Madeleine, Gocke, Christopher D, Antin, Joseph H, Nikiforow, Sarah, DeZern, Amy E, Chen, Yi-Bin, Ho, Vincent T, Jones, Richard J, Lennon, Niall J, Walt, David R, Ritz, Jerome, Soiffer, Robert J, Gondek, Lukasz P, Lindsley, R Coleman

“…Clonal hematopoiesis (CH) can be transmitted from a donor to a recipient during allogeneic hematopoietic cell transplantation. Exclusion of candidate donors…”
Get full text

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease by Koreth, John, Kim, Haesook T., Jones, Kyle T., Lange, Paulina B., Reynolds, Carol G., Chammas, Marie J., Dusenbury, Katherine, Whangbo, Jennifer, Nikiforow, Sarah, Alyea, Edwin P., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Chen, Yi-Bin, Avigan, David, Blazar, Bruce R., Antin, Joseph H., Ritz, Jerome, Soiffer, Robert J.

“…Chronic graft-versus-host disease (cGVHD) is associated with inadequate reconstitution of tolerogenic CD4+CD25+FOXP3+ regulatory T cells (Tregs). Previous…”
Get full text

A disease risk index for patients undergoing allogeneic stem cell transplantation by Armand, Philippe, Gibson, Christopher J., Cutler, Corey, Ho, Vincent T., Koreth, John, Alyea, Edwin P., Ritz, Jerome, Sorror, Mohamed L., Lee, Stephanie J., Deeg, H. Joachim, Storer, Barry E., Appelbaum, Frederick R., Antin, Joseph H., Soiffer, Robert J., Kim, Haesook T.

“…The outcome of allogeneic HSCT varies considerably by the disease and remission status at the time of transplantation. Any retrospective or prospective HSCT…”
Get full text

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation by Davids, Matthew S., Kim, Haesook T., Costello, Caitlin, Herrera, Alex F., Locke, Frederick L., Maegawa, Rodrigo O., Savell, Alexandra, Mazzeo, Michael, Anderson, Adrienne, Boardman, Alexander P., Weber, Augustine, Avigan, David, Chen, Yi-Bin, Nikiforow, Sarah, Ho, Vincent T., Cutler, Corey, Alyea, Edwin P., Bachireddy, Pavan, Wu, Catherine J., Ritz, Jerome, Streicher, Howard, Ball, Edward D., Bashey, Asad, Soiffer, Robert J., Armand, Philippe

“…Programmed cell death-1 (PD-1)/programmed death ligand-1 blockade may potentially augment graft-vs-tumor effects following allogeneic hematopoietic cell…”
Get full text

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation by Cutler, Corey, Multani, Pratik, Robbins, David, Kim, Haesook T., Le, Thuy, Hoggatt, Jonathan, Pelus, Louis M., Desponts, Caroline, Chen, Yi-Bin, Rezner, Betsy, Armand, Philippe, Koreth, John, Glotzbecker, Brett, Ho, Vincent T., Alyea, Edwin, Isom, Marlisa, Kao, Grace, Armant, Myriam, Silberstein, Leslie, Hu, Peirong, Soiffer, Robert J., Scadden, David T., Ritz, Jerome, Goessling, Wolfram, North, Trista E., Mendlein, John, Ballen, Karen, Zon, Leonard I., Antin, Joseph H., Shoemaker, Daniel D.

“…Umbilical cord blood (UCB) is a valuable source of hematopoietic stem cells (HSCs) for use in allogeneic transplantation. Key advantages of UCB are rapid…”
Get full text

Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation by Yu, Lijian, Kim, Haesook T, Kasar, Siddha, Benien, Parul, Du, Wei, Hoang, Kevin, Aw, Andrew, Tesar, Bethany, Improgo, Reina, Fernandes, Stacey, Radhakrishnan, Saranya, Klitgaard, Josephine, Lee, Charles, Getz, Gad, Setlur, Sunita R, Brown, Jennifer R

“…Chronic lymphocytic leukemia (CLL) with 17p deletion typically progresses quickly and is refractory to most conventional therapies. However, some del(17p)…”
Get full text

Splenic irradiation prior to allogeneic hematopoietic cell transplantation for patients with myelofibrosis by Bales, John R., Kim, Haesook T., Portillo, Roxana, Patel, Chirayu, McAfee, Steven, Dey, Bimalangshu, Spitzer, Thomas, Chen, Yi-Bin, El-Jawahri, Areej, DeFilipp, Zachariah, Hobbs, Gabriela S.

Get full text

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation by Armand, Philippe, Kim, Haesook T., Cutler, Corey S., Ho, Vincent T., Koreth, John, Alyea, Edwin P., Soiffer, Robert J., Antin, Joseph H.

“…Iron overload could be a significant contributor to treatment-related mortality (TRM) for patients with hematologic malignancies undergoing hematopoietic stem…”
Get full text

Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation by Cutler, Corey, Kim, Haesook T., Sun, Lixian, Sese, Doreen, Glotzbecker, Brett, Armand, Philippe, Koreth, John, Ho, Vincent, Alyea, Edwin, Ballen, Karen, Ritz, Jerome, Soiffer, Robert J., Milford, Edgar, Antin, Joseph H.

“…Using a uniform detection method for donor-specific anti-HLA antibodies (DSAs), we sought to determine the effect of preformed DSAs on outcomes in double…”
Get full text

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation by Penter, Livius, Zhang, Yi, Savell, Alexandra, Huang, Teddy, Cieri, Nicoletta, Thrash, Emily M., Kim-Schulze, Seunghee, Jhaveri, Aashna, Fu, Jingxin, Ranasinghe, Srinika, Li, Shuqiang, Zhang, Wandi, Hathaway, Emma S., Nazzaro, Matthew, Kim, Haesook T., Chen, Helen, Thurin, Magdalena, Rodig, Scott J., Severgnini, Mariano, Cibulskis, Carrie, Gabriel, Stacey, Livak, Kenneth J., Cutler, Corey, Antin, Joseph H., Nikiforow, Sarah, Koreth, John, Ho, Vincent T., Armand, Philippe, Ritz, Jerome, Streicher, Howard, Neuberg, Donna, Hodi, F. Stephen, Gnjatic, Sacha, Soiffer, Robert J., Liu, X. Shirley, Davids, Matthew S., Bachireddy, Pavan, Wu, Catherine J.

“…Relapsed myeloid disease after allogeneic stem cell transplantation (HSCT) remains largely incurable. We previously demonstrated the potent activity of immune…”
Get full text

Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease by Sarantopoulos, Stefanie, Stevenson, Kristen E., Kim, Haesook T., Cutler, Corey S., Bhuiya, Nazmim S., Schowalter, Michael, Ho, Vincent T., Alyea, Edwin P., Koreth, John, Blazar, Bruce R., Soiffer, Robert J., Antin, Joseph H., Ritz, Jerome

“…Chronic graft-versus-host disease (cGVHD) causes significant morbidity and mortality in patients otherwise cured of malignancy after hematopoietic stem cell…”
Get full text

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation by Kim, Haesook T, Baker, Peter O, Parry, Erin, Davids, Matthew, Alyea, Edwin P, Ho, Vincent T, Cutler, Corey, Koreth, John, Gooptu, Mahasweta, Romee, Rizwan, Nikiforow, Sarah, Antin, Joseph H, Ritz, Jerome, Soiffer, Robert J, Wu, Catherine J, Brown, Jennifer R

Get full text

Bortezomib-Based Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Transplantation by KORETH, John, STEVENSON, Kristen E, SOIFFER, Robert J, RITZ, Jerome, ALYEA III, Edwin P, KIM, Haesook T, MCDONOUGH, Sean M, BINDRA, Bhavjot, ARMAND, Philippe, HO, Vincent T, CUTLER, Corey, BLAZAR, Bruce R, ANTIN, Joseph H

“…HLA-mismatched unrelated donor (MMUD) hematopoietic stem-cell transplantation (HSCT) is associated with increased graft-versus-host disease (GVHD) and impaired…”
Get full text

Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial by Cutler, Corey, Kim, Haesook T., Bindra, Bhavjot, Sarantopoulos, Stefanie, Ho, Vincent T., Chen, Yi-Bin, Rosenblatt, Jacalyn, McDonough, Sean, Watanaboonyongcharoen, Phandee, Armand, Philippe, Koreth, John, Glotzbecker, Brett, Alyea, Edwin, Blazar, Bruce R., Soiffer, Robert J., Ritz, Jerome, Antin, Joseph H.

“…B cells are implicated in the pathophysiology of chronic graft-vs-host disease (GVHD), and phase 2 trials suggest that B cell depletion can treat established…”
Get full text

High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease by SARANTOPOULOS, Stefanie, STEVENSON, Kristen E, KIM, Haesook T, BHUIYA, Nazmim S, CUTLER, Corey S, SOIFFER, Robert J, ANTIN, Joseph H, RITZL, Jerome

“…Purpose: Recent studies suggest that donor B cells as well as T cells contribute to immune pathology in patients with chronic graft-versus-host disease (GVHD)…”
Get full text

Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation by Rambaldi, Benedetta, Kim, Haesook T., Arihara, Yohei, Asano, Takeru, Reynolds, Carol, Manter, Mariah, Halpern, Max, Weber, Augustine, Koreth, John, Cutler, Corey, Gooptu, Mahasweta, Nikiforow, Sarah, Ho, Vincent T., Antin, Joseph H., Romee, Rizwan, Ampudia, Jeanette, Ng, Cherie, Connelly, Stephen, Soiffer, Robert J., Ritz, Jerome

“…CD6 is a co-stimulatory receptor expressed on T cells that binds activated leukocyte cell adhesion molecule (ALCAM), expressed on antigen presenting cells,…”
Get full text